The Real Monthly Cost of GLP-1s in 2026 (Every Path Compared)

The monthly cost of a GLP-1 in 2026 ranges from a $50 Medicare copay to a list price above $1,300 for the same brand drug — the difference is entirely about which path you take to get it. Almost no one pays the sticker price. Between manufacturer self-pay programs, the new federal TrumpRx platform, insurance coverage, the Medicare GLP-1 Bridge, and compounded options, most people can find a route well under $500 a month, and many pay far less.

Why "How Much Does It Cost?" Has No Single Answer

Ask what a GLP-1 costs and the honest answer is a question back: how are you paying for it? The list price — the number the manufacturer sets — is almost a fiction for the individual patient. It matters for insurers and pharmacy benefit managers negotiating behind the scenes, but the person at the counter almost never pays it. What you actually pay depends on your insurance, your diagnosis, whether you qualify for a government program, and whether you are willing to buy directly from the manufacturer or a telehealth pharmacy.

This guide lays out every path as it stands in mid-2026, with real numbers, so you can see where you fit. For a real-time snapshot of provider pricing that we update as it changes, our GLP-1 prices today page is the companion to this evergreen comparison.

The List Prices (What Almost No One Pays)

Start with the sticker, because it frames everything else. As of mid-2026, the published U.S. list prices are approximately:

• Wegovy (semaglutide): about $1,349 per month
• Zepbound (tirzepatide): above $1,080 per month
• Ozempic (semaglutide, diabetes label): up to roughly $1,000 per month
• Mounjaro (tirzepatide, diabetes label): around $1,080 per month or more

These numbers are why GLP-1 affordability became a national policy issue. They are also increasingly disconnected from reality: the manufacturers, the federal government, and telehealth pharmacies have all built lower-cost channels precisely because the list price prices out most of the people who could benefit. The rest of this article is really about those channels.

Path 1: Buying Brand Direct From the Manufacturer

Both Novo Nordisk and Eli Lilly now sell their brand GLP-1s directly to cash-paying patients at a steep discount to list, cutting out the insurance middle layer.

Wegovy through NovoCare

Novo Nordisk's NovoCare Pharmacy sells Wegovy on a self-pay basis. As of mid-2026, the standard self-pay rate is about $349 per month for the injectable pen doses, with an introductory rate of $199 per month for the first two fills (0.25 mg and 0.5 mg) for patients new to the program, available through the end of 2026. The oral Wegovy tablet is offered at $149 per month for the 4 mg dose during a limited window. These prices are for people paying cash, not billing insurance.

Zepbound through LillyDirect

Eli Lilly's LillyDirect self-pay program sells Zepbound single-dose vials at tiered prices: about $299 per month for the 2.5 mg starter dose, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg doses. There is a catch worth knowing: to keep the lower pricing, patients generally must refill within 45 days of their previous delivery, or the per-vial price steps up substantially. The vials require a bit more hands-on preparation than an autoinjector pen, which is the trade-off for the lower price.

For most uninsured patients who want the FDA-approved brand product with a documented supply chain, these manufacturer programs are the simplest reliable route — and far cheaper than the list price suggests.

Path 2: The TrumpRx Direct Platform

In 2026, the federal government entered the pricing picture directly. Under Executive Order 14297, "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," the administration reached agreements with Novo Nordisk and Eli Lilly to offer most-favored-nation pricing on semaglutide and tirzepatide, and launched a direct-to-consumer platform, TrumpRx.gov, to sell them.

Through TrumpRx, brand GLP-1 vials are offered to cash payers at an average of about $350 per month. Reported specifics include Zepbound dropping from more than $1,080 to an average near $346, and Novo Nordisk's semaglutide products moving toward roughly $350 — a large cut from list. The agreements also signaled lower entry pricing (around $150 per month) for initial doses of future FDA-approved oral GLP-1 drugs. As with any new government program, coverage, dose availability, and the exact checkout experience are still settling, so verify current terms directly before relying on a specific price.

Path 3: Commercial Insurance (When It Covers Obesity Drugs)

If your employer or marketplace plan covers GLP-1s for weight management, this is often the cheapest route — but coverage is far from universal, and it comes with gatekeeping. Many plans still exclude anti-obesity medications entirely, or cover them only for diabetes. When a plan does cover the drug, your out-of-pocket cost depends on the formulary tier and typically lands anywhere from a modest copay to over $100 per month. Manufacturer copay savings cards can lower the cost further for eligible patients with commercial (non-government) insurance.

The friction here is administrative rather than financial: expect prior authorization, documentation of your BMI and any qualifying conditions, and sometimes step therapy — a requirement to try and fail a cheaper option first. A prescription that meets FDA criteria can still be denied on these grounds, which is why so many people who technically qualify end up exploring the cash and telehealth routes. Our eligibility guide walks through the criteria insurers scrutinize.

Path 4: The Medicare GLP-1 Bridge ($50/Month)

For years, Medicare was statutorily barred from covering medications used specifically for weight loss. That wall developed a door in 2026. The Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge, a demonstration program running from July 1, 2026 through December 31, 2027, that gives eligible Part D beneficiaries certain weight-management GLP-1s for a $50 monthly copay, with the Part D deductible waived.

The program covers specific products — the pill and injectable formulations of Wegovy, the KwikPen formulation of Zepbound, and the Foundayo oral semaglutide pill — for beneficiaries enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage. Clinical eligibility follows a tiered structure: a BMI of 35 or higher; or a BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. Prior authorization applies, and a KFF analysis estimated that roughly 3.8 million beneficiaries could meet the criteria. Beneficiaries can check eligibility at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE.

One caveat: the $50 copay does not count toward your true out-of-pocket (TrOOP) threshold, and there is no low-income subsidy applied within the demonstration. Still, for eligible older adults previously facing a four-figure cash price, this is the single largest access change of the year.

Path 5: Compounded GLP-1s Through Telehealth

Compounded semaglutide and tirzepatide exploded in popularity during the 2023-2024 shortages, when pharmacies were permitted to make copies of drugs the FDA had listed as in short supply. That window has largely closed. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, which removed the legal basis for mass compounding of copies, and the agency has since moved to further restrict it. Individualized compounding by a 503A pharmacy for a specific patient — for example, a documented clinical need for a different formulation — can still be permissible in defined circumstances, but the era of cheap, mass-produced compounded GLP-1s is ending.

Where it remains available, telehealth pricing for compounded semaglutide commonly runs from roughly $169 to $499 per month, and compounded tirzepatide often lands around $199 to $349 per month, frequently plus a membership or consultation fee. Some platforms advertise introductory rates well below that. The cost savings are real, but so are the trade-offs: compounded products are not FDA-approved, quality control varies by pharmacy, and the legal ground is shifting. If you go this route, confirm the pharmacy's licensure and legal footing, and read our deeper comparison of compounded vs. brand-name semaglutide first.

Every Path, Side by Side

How to Find Your Cheapest Legitimate Path

The logic is simpler than the table looks. If you have Medicare and meet the Bridge criteria, that $50 copay is hard to beat. If you have commercial insurance, ask your plan directly whether it covers anti-obesity medication and what the prior-authorization requirements are — a covered prescription with a copay card is often the lowest cost of all. If you are paying cash and want the brand product, compare the manufacturer self-pay programs against TrumpRx pricing for your specific drug and dose. And if budget is the binding constraint, compounded telehealth can be the least expensive route, provided you have vetted the pharmacy and understand that the regulatory landscape is tightening.

Whatever path you choose, the decision to start, switch, or stop a GLP-1 belongs in a conversation with a prescriber. If you are still deciding whether a GLP-1 is right for you at all, our 2-minute quiz can point you toward the questions worth asking, and our provider reviews compare the telehealth programs that handle each of these payment routes.

The Bottom Line

The gap between $50 and $1,349 a month for the identical molecule is the story of GLP-1 access in 2026. The list price is a starting point for negotiation you never see, not a bill you have to pay. Between manufacturer programs, the TrumpRx platform, insurance, the new Medicare Bridge, and compounded options, the practical question is not "can I afford a GLP-1?" so much as "which of these five doors is open to me?" For most people, at least one is — and it costs a fraction of the sticker.

Related Articles

• GLP-1 Prices Today: Live Provider Pricing Tracker
• Am I Eligible for a GLP-1? Full Screening Guide
• Do You Qualify for a GLP-1? The 2026 Eligibility Guide
• Compounded vs Brand-Name Semaglutide: What's the Difference?

References

• Centers for Medicare & Medicaid Services. "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." CMS Newsroom, 2026. cms.gov — Medicare GLP-1 Bridge terms, covered products, and $50 copay.
• Centers for Medicare & Medicaid Services. "Medicare GLP-1 Bridge." CMS coverage page, 2026. cms.gov — Eligibility criteria, deductible/TrOOP treatment, program dates.
• KFF. "Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge." 2026. kff.org — Estimated eligible population.
• NovoCare. "Wegovy (semaglutide) Cost, Coverage & Savings" and self-pay price guide. Novo Nordisk, 2026. novocare.com — Wegovy list price and NovoCare self-pay rates.
• Eli Lilly. "Zepbound Self-Pay Terms & Conditions" (LillyDirect). 2026. lilly.com — Zepbound single-dose vial self-pay pricing and refill terms.
• The White House. "Savings from Most-Favored-Nation Drug Pricing Policy." 2026. whitehouse.gov — Executive Order 14297 and MFN framework.
• AMCP. "Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s." 2026. amcp.org — TrumpRx platform pricing for semaglutide and tirzepatide.
• Pharmacy Times. "FDA Moves to Permanently Close the Door on Compounded GLP-1s." 2026. pharmacytimes.com — Post-shortage compounding restrictions and enforcement timeline.
• Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 384(11):989-1002. — STEP 1 efficacy context.
• Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 387(3):205-216. — SURMOUNT-1 efficacy context.